Clinical study of ursodeoxycholic acid combined with reduced glutathione for non-alcoholic fatty liver disease

Abstract

Objective To explore the clinical curative effect of ursodeoxycholic acid combined with reduced glutathione for non-alcoholic fatty liver disease. Methods 128 patients with non-alcoholic fatty liver disease in our hospital were selected, and they were randomly divided into control group and research group, 64 cases in each group. The control group received ursodeoxycholic acid capsules, the research group received reduced glutathione tablet on the basis of ursodeoxycholic acid capsules, the two groups received treatment of two periods, each period had one and half months. The liver function and blood lipid were detected and compared between the two groups. Results The total clinical effective rate of the research group was 93.75%, which of the control group was 68.75% (χ2=20.5, P=0.000), the difference was statistically significant. After treatment, liver function (ALT, AST, TBIL, GGT and ALP) and lipid levels (TG and CHO) of the two groups were improved significantly[the control group: before treatment (138.75±30.63) IU/L, (161.72±55.61) IU/L, (183.65±58.47) μmol/L, (213.65±40.35) IU/L, (82.38±23.15) IU/L, (2.85±0.77) μmol/L, (6.45±0.37) μmol/L, after treatment (66.38±26.31) IU/L, (65.39±22.15) IU/L, (92.38±36.15) μmol/L, (99.68±36.72) IU/L, (30.23±10.36) IU/L, (1.92±0.58) mol/L, (5.39±0.53) μmol/L; the research group before treatment (141.25±32.53) IU/L, (157.56±58.31) IU/L, (190.23±51.27) μmol/L, (223.72±43.18) IU/L, (80.86±21.85) IU/L, (2.92±0.73) μmol/L, (6.43±0.82) μmol/L, after treatment (37.64±11.25) IU/L, (36.25±11.83) IU/L, (47.67±8.32) μmol/L, (70.52±26.31) IU/L, (16.69±7.32) IU/L, (1.32±0.63) μmol/L, (4.31±0.63) μmol/L], the differences were statistically significant(the control group : t=14.3, 12.9, 10.6, 16.7, 16.4, 7.7, 13.1, all P<0.01; the research group: t=24.1, 25.4, 21.9, 24.2, 16.1, 13.3, 16.4, all P<0.01), but these indicators of the research group were improved significantly better than those of the control group, the differences were statistically significant(t=8.0, 9.3, 9.6, 8.5, 8.5, 5.6, 10.5; all P<0.01). Conclusion The clinical curative effect of research group is distinct, safe and has no obvious adverse reactions, which is worthy of clinical application. Key words: Ursodeoxycholic acid; Reduced glutathione; Fatty liver